Cover Story
Guest Editorial
Over and over again, I’ve seen the same missteps, clumsy excuses, and faulty logic during sponsor presentations to the FDA Oncologic Drugs Advisory Committee, repeated as if part of a tragic, regulatory update to the movie Groundhog Day.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- As fire encroached, City of Hope prepared to evacuate its Duarte campus
- Rathmell steps down at NCI as Trump team considers candidates to replace her
Wafik El-Deiry, Harvey Risch have been interviewed - Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency
- New colorectal cancer screening strategies must advance the standard of care
- Weeks before death from sarcoma, Norm Coleman reflected on his career in radiation oncology and addressing health disparities